Clinical Trials on Prostate Hypertrophy

Total 7641 results

Northwestern University
National Cancer Institute (NCI)

Terminated

Genistein in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Millennium: The Takeda Oncology Company

Completed

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
ORIC Pharmaceuticals

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer | Neuroendocrine Prostate Cancer

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Visually Enhanced Education About Prostate Cancer

Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer

Recurrent Prostate Carcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Hormone-Resistant Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Stereotactic Radiation for Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Nagoya University

Unknown

Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy (EARTH)

Hypertensive Left Ventricular Hypertrophy

Japan
AstraZeneca

Completed

Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer (REMPRO)

Metastatic Castration-resistant Prostates Cancer

India, Peru, Saudi Arabia, Egypt, Colombia, Korea, Republic of, Turkey, United Arab Emirates
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI); Prostate Cancer Foundation

Terminated

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
John P. Fruehauf
Sanofi

Terminated

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Recurrent Prostate Cancer | Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Heart Centre Singapore

Unknown

MRI Sequence and Imaging Protocol Development (BikeMRI)

Hypertension | Ischemic Heart Disease | Cardiomyopathy, Dilated | Cardiomyopathy, Hypertrophic | Left Ventricular Hypertrophy

Singapore
Sanjay Gupta PhD

Terminated

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Mayo Clinic

Completed

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Colorado, Denver
EDAP TMS S.A.

Completed

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer (EASE)

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer Castration-resistant Prostate Cancer

China
Community Cancer Center, Normal, Illinois

Unknown

A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors

Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Genetic Analysis of Familial Hypertrophic Cardiomyopathy

Heart Diseases | Cardiovascular Diseases | Cardiomyopathy, Hypertrophic | Myocardial Diseases
National Cancer Institute (NCI)

Completed

AMG 386 and Abiraterone for Advanced Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Neoplasm, Prostate | Neoplasm,Prostatic

United States
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Comparison of Prostate Fusion Biopsies With Software and Cognitive

Prostate Cancer Detection | Fusion Prostate Biopsy

Spain
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
AstraZeneca

Recruiting

The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (PROspect)

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer

China
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate

United States
Cliniques universitaires Saint-Luc- Université...
Sanofi

Completed

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Metastatic Prostate Cancer | Hormone Resistant Prostate Cancer

Belgium, Luxembourg
Yale University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Exercise in Genetic Cardiovascular Conditions (LIVE-HCM/LQT)

Hypertrophic Cardiomyopathy | Long QT Syndrome

United States, United Kingdom, Canada, Australia, New Zealand
University of California, Irvine

Withdrawn

The Genetics of Cardiomyopathy and Heart Failure

Dilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive Cardiomyopathy | Mitochondrial Cardiomyopathy | Noncompaction Cardiomyopathy

United States
National Cancer Institute (NCI)

Active, not recruiting

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Prostate Cancer | Neoplasms of Prostate | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

Evaluation of the Metastasis and Recurrence of Prostate Cancer

Prostate Cancer Recurrent | Prostate Cancer Metastatic | Prostate Cancer (Diagnosis) | Prostate Cancer Stage

China
Tianjin Medical University Second Hospital

Recruiting

Selective Treatment According to Molecular Subtype of Prostate Cancer (STAMP)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Prostate Cancer | Prostate Neoplasms | Castration Resistant Prostate Cancer (CRPC)

Japan
University of Southern California
National Cancer Institute (NCI)

Terminated

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
St. Luke's Medical Center, Philippines

Completed

Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome

Benign Prostatic Hyperplasia | Prostate Cancer | Prostatitis

Philippines

Clinical Trials on Prostate Hypertrophy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations